anti-CD19 DASH CAR-T / Hrain Biotech 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
anti-CD19 DASH CAR-T / Hrain Biotech
NCT05651191: To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

Recruiting
1
9
RoW
Human CD19 Targeted DASH CAR-T Cells Injection, CD19 DASH CAR-T
Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University
B-cell Acute Lymphoblastic Leukemia
09/24
09/25

Download Options